UBS Maintains Neutral on AbbVie, Raises Price Target to $295
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice TargetHot
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $275 to $295.
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $275 to $295.